Nursing in critical care · 2026
Risk Factors for Antibiotic-Associated Diarrhoea in Paediatric Patients With Severe Pneumonia: A Retrospective Cohort.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gao Shuang, Dan Ya, Liu Xuemei, Tang Ruxin, Wang Gengqin
Аннотация
BACKGROUND: Severe pneumonia in paediatric patients typically necessitates prolonged courses of antibiotic therapy, a practice that elevates vulnerability to antibiotic-associated diarrhoea (AAD).
AIM: The present study aimed to evaluate the clinical profiles of paediatric patients with AAD secondary to severe pneumonia and to explore evidence-based nursing interventions for this complication.
STUDY DESIGN: A retrospective cohort. This study was conducted at a tertiary hospital in China, enrolling paediatric patients diagnosed with severe pneumonia. To identify independent risk factors for AAD development, a stepwise analytical framework was applied, comprising univariate analysis, correlation analysis and multivariate logistic regression modelling.
RESULTS: A total of 306 children with severe pneumonia were included. The overall incidence of secondary AAD among this cohort was 13.73% (42/306). The median time from antibiotic initiation to AAD onset was 5 days (IQR 3-8 days). Multivariate logistic regression analysis identified five independent risk factors for AAD: age < 1 year (odds ratio [OR] = 2.246, 95% confidence interval [CI]: 1.821-2.909), administration of penicillin-class antibiotics (OR = 2.474, 95% CI: 2.043-3.061), antibiotic treatment duration ≥ 1 week (OR = 2.970, 95% CI: 2.127-3.507), requirement for mechanical ventilation (OR = 3.049, 95% CI: 2.895-3.725), and hospital stay > 14 days (OR = 1.954, 95% CI: 1.630-2.402). In contrast, prophylactic probiotic administration was identified as a protective factor against AAD (OR = 0.801, 95% CI: 0.586-0.944).
CONCLUSIONS: In clinical practice, stratified management protocols should be implemented for paediatric populations at high risk of AAD.
RELEVANCE TO CLINICAL PRACTICE: Core components of such protocols include optimising antibiotic selection and treatment duration, initiating early combined probiotic interventions and enhancing intestinal function monitoring.
AIM: The present study aimed to evaluate the clinical profiles of paediatric patients with AAD secondary to severe pneumonia and to explore evidence-based nursing interventions for this complication.
STUDY DESIGN: A retrospective cohort. This study was conducted at a tertiary hospital in China, enrolling paediatric patients diagnosed with severe pneumonia. To identify independent risk factors for AAD development, a stepwise analytical framework was applied, comprising univariate analysis, correlation analysis and multivariate logistic regression modelling.
RESULTS: A total of 306 children with severe pneumonia were included. The overall incidence of secondary AAD among this cohort was 13.73% (42/306). The median time from antibiotic initiation to AAD onset was 5 days (IQR 3-8 days). Multivariate logistic regression analysis identified five independent risk factors for AAD: age < 1 year (odds ratio [OR] = 2.246, 95% confidence interval [CI]: 1.821-2.909), administration of penicillin-class antibiotics (OR = 2.474, 95% CI: 2.043-3.061), antibiotic treatment duration ≥ 1 week (OR = 2.970, 95% CI: 2.127-3.507), requirement for mechanical ventilation (OR = 3.049, 95% CI: 2.895-3.725), and hospital stay > 14 days (OR = 1.954, 95% CI: 1.630-2.402). In contrast, prophylactic probiotic administration was identified as a protective factor against AAD (OR = 0.801, 95% CI: 0.586-0.944).
CONCLUSIONS: In clinical practice, stratified management protocols should be implemented for paediatric populations at high risk of AAD.
RELEVANCE TO CLINICAL PRACTICE: Core components of such protocols include optimising antibiotic selection and treatment duration, initiating early combined probiotic interventions and enhancing intestinal function monitoring.